Abadías-Granado I, Diago A, Cerro P A, Palma-Ruiz A M, Gilaberte Y
Servicio de Dermatología, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Servicio de Dermatología, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Actas Dermosifiliogr (Engl Ed). 2021 May 11. doi: 10.1016/j.adengl.2021.05.011.
Leishmaniasis is a chronic disease caused by flagellate protozoa of the genus Leishmania. It is a global disease, but most cases are seen in South America, the Mediterranean, and some areas of Asia and Africa. The 3 main types of leishmaniasis are cutaneous (the most common), mucocutaneous, and visceral (the most severe). Visceral leishmaniasis is also known as kala-azar. Leishmaniasis is diagnosed by demonstrating the presence of Leishmania amastigotes in clinical specimens using direct microscopic examination or molecular analysis. Various treatments exist, although the evidence supporting the options available for cutaneous leishmaniasis is weak. Both the classical presentation of leishmaniasis and our management of the disease have changed in recent decades because of acquired immune deficiency caused by conditions such as human immunodeficiency infection or the use of tumor necrosis factor inhibitors.
Actas Dermosifiliogr (Engl Ed). 2021-5-11
Actas Dermosifiliogr (Engl Ed). 2021-2-27
Braz J Infect Dis. 2014
Acta Otorrinolaringol Esp (Engl Ed). 2021
Hautarzt. 2008-8
Appl Microbiol Biotechnol. 2020-10
Cureus. 2023-2-11
Indian Dermatol Online J. 2025-4-15
Cureus. 2025-3-21
Am J Trop Med Hyg. 2025-2-18